In this article, we will list the 5 Best Low-Priced Stocks to Get Rich in 2026. Please visit 10 Best Low-Priced Stocks to Get Rich in 2026 if you would like to see the extended list and the methodology behind it.
5. PowerFleet, Inc. (NASDAQ:AIOT)
Upside Potential as of June 18, 2026: 126.13%
Number of Hedge Fund Holders: 32
On June 16, Raymond James cut the price target on PowerFleet, Inc. (NASDAQ:AIOT) to $7, down from $8. This comes despite the company’s Q4 results surpassing expectations and a strengthened FY27 outlook pointing to stronger growth and profitability into year-end.
As noted by Raymond James, the improved performance will be driven by various factors, including solid subscription-based services growth, surging annual recurring revenue, and enhanced adoption. The firm has an Outperform rating on the stock.
Gods_Kings/Shutterstock.com
Moreover, accelerating demand for AI video and in-warehouse solutions, along with channel growth and margin expansion, point to the same positive, bigger-picture trend, the firm added. Thanks to these drivers, PowerFleet, Inc. (NASDAQ:AIOT) is one of the best low-priced stocks to get rich in 2026.
In PowerFleet, Inc.’s (NASDAQ:AIOT) results delivered a day earlier, total revenue and adjusted EBITDA were up 11% YoY and 42% YoY, respectively, in Q4. The company remains focused on investments in go-to-market capabilities, channel partnerships, and South African deployment.
PowerFleet, Inc. (NASDAQ:AIOT) is a New Jersey-based provider of artificial intelligence-of-things (AIoT) solutions. Founded in 1993, the company provides a unity solution portfolio, as well as hosting, maintenance, and consulting services.
4. Black Rock Coffee Bar, Inc. (NASDAQ:BRCB)
Upside Potential as of June 18, 2026: 133.16%
Number of Hedge Fund Holders: 23
On June 8, Piper Sandler started coverage on Black Rock Coffee Bar, Inc. (NASDAQ:BRCB) with a Neutral rating and a price target of $9. The firm believes there is a balanced risk/reward at current share levels, saying that the company’s significant growth potential over the long-term is offset by a “difficult” macro environment, intense competition, and its own high performance benchmark.
The company’s expansion isn’t something hidden. On June 10, Black Rock Coffee Bar, Inc. (NASDAQ:BRCB) announced the opening of a new store in Harker Heights. The company now operates more than 190 retail locations across seven states. As said by the CEO Mark Davis,
“We’re thrilled to continue growing in Austin and to bring the Black Rock experience to even more neighborhoods across the Austin Metro Area.”
With a one-year median price target of $18, Black Rock Coffee Bar, Inc. (NASDAQ:BRCB) has an upside potential of 133.16% from the current level. Thus, it has secured a spot on our list of the best low-priced stocks to get rich in 2026.
Black Rock Coffee Bar, Inc. (NASDAQ:BRCB) is an Arizona-based company owning a chain of drive-thru coffee bars. Incorporated in 2008, the company offers espresso-based drinks, energy drinks, and an assortment of snacks.
3. Ardelyx, Inc. (NASDAQ:ARDX)
Upside Potential as of June 18, 2026: 164.46%
Number of Hedge Fund Holders: 34
On June 16, Ladenburg started coverage on Ardelyx, Inc. (NASDAQ:ARDX) with a Buy rating and a price target of $16. According to TheFly, the company is currently focused on expanding demand for Ibsrela, sustaining sales momentum for Xphozah, growing its pipeline, and meeting financial projections.
When Ardelyx, Inc. (NASDAQ:ARDX) reported its Q1 FY2026 results, its total product revenue was up 38% YoY, thanks to 58% YoY surge in IBSRELA revenue and strong XPHOZAH performance. While discussing IBSRELA, management laid out plans to deliver at least $1 billion in annual revenue in 2029. What strengthens the case for the company is its financial flexibility to make additional investments.
As stated by the President and CEO, Mike Raab,
“We’re excited for this next phase of Ardelyx’s evolution as we execute on our pipeline and explore various external opportunities that align with our mission and core capabilities and meet our disciplined capital allocation approach.”
With a 1-year return outperformance of 42.18% and upside potential of 133.16%, Ardelyx, Inc. (NASDAQ:ARDX) is among the best low-priced stocks to get rich in 2026.
Ardelyx, Inc. (NASDAQ:ARDX) is a Massachusetts-based company specializing in treatments for underserved medical needs. The company offers a small-molecule therapy and a phosphate-absorption inhibitor to treat irritable bowel syndrome and chronic kidney disease, respectively.
2. Avalo Therapeutics, Inc. (NASDAQ:AVTX)
Upside Potential as of June 18, 2026: 195.92%
Number of Hedge Fund Holders: 37
On June 12, BofA started coverage on Avalo Therapeutics, Inc. (NASDAQ:AVTX) with a Buy rating and a price target of $35. According to the firm, the company is a “cleaner, single-asset immunology story” following the positive Phase 2 data in hidradenitis suppurativa. If the company’s lead product, abdakibart, is compared with alternative drugs, the former may provide a more convenient monthly dosing schedule and greater impact on disease outcomes, the firm added.
BofA views the investment case as “a differentiated IL-1β antibody in HS, a large undertreated market, and a balance sheet with runway through next major data readout into 2029e after ~$405M net proceeds.”
The company’s one-year return is what catches the eye, with an impressive 183% market outperformance. This doesn’t stop here as the company’s future looks equally promising. With a bullish stance from all 14 analysts covering the stock, Avalo Therapeutics, Inc. (NASDAQ:AVTX) has a 1-year upside potential of 195.92%. No wonder AVTX is among the best low-priced stocks to get rich in 2026.
Avalo Therapeutics, Inc. (NASDAQ:AVTX), incorporated in 2011, is a Pennsylvania-based clinical-stage biotechnology company that provides solutions for immune-mediated inflammatory diseases. The company’s lead candidate is AVTX-009.
1. Upstream Bio, Inc. (NASDAQ:UPB)
Upside Potential as of June 18, 2026: 572.00%
Number of Hedge Fund Holders: 34
On June 12, JPMorgan significantly trimmed the price target on Upstream Bio, Inc. (NASDAQ:UPB) to $8 from $35, while downgrading the stock from Overweight to Neutral. In a research note, the analyst said that other peers in asthma are also set to generate new data over the course of the company’s Verekitug’s late-stage development. Thus, the results from these competitors are important to understand where the company’s product stands.
According to JPMorgan, the rest of the year and beyond appear as an execution period for the company, with “relatively sparse near-term stock-moving catalysts.” The firm finds it difficult to see a path to upside in the near term, especially given the company’s additional cash needs to power phase 3 development. The company’s negative returns are understandable, considering its 572% upside potential. With strong potential for future gains, Upstream Bio, Inc. (NASDAQ:UPB) is among the best low-priced stocks to get rich in 2026.
Back on June 3, Matthew Caufield from H.C. Wainwright began coverage of Upstream Bio, Inc. (NASDAQ:UPB) with a Buy rating and $36 price target. The analyst believes Verekitug is a novel antibody antagonist of the thymic stromal lymphopoietin receptor, with “sights on efficacy and differentiated quarterly subcutaneous dosing.”
Upstream Bio, Inc. (NASDAQ:UPB), incorporated in 2021, is a Massachusetts-based clinical-stage biotechnology company specializing in solutions for severe respiratory disorders.
While we acknowledge the potential of UPB to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than UPB and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: Starter Stock Portfolio: 14 Safe Stocks to Buy Now and 40 Most Popular Stocks Among Hedge Funds Heading Into 2026.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
